Oculis Holding AG Investigation - OCS

Company
Oculis Holding AG (NASDAQ: OCS)

Learn more about the Oculis Holding AG Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Oculis Holding AG Investigation Details

Multiple SEC filings made prior to the stock collapse continued to present the OCS-01 DME program as progressing toward regulatory approval. A prospectus supplement filed on October 31, 2025 stated that topline results from the DIAMOND trials were "expected in the second quarter of 2026,” with a subsequent New Drug Applications (NDAs) submission to the U.S. FDA to begin in Q4 2026. A 6-K filed on October 6, 2025 described Oculis as being "in a strong position with multiple pivotal studies, targeting multi-billion-dollar markets" in connection with the DME program. The Company ultimately disclosed that the pivotal DIAMOND trials failed and announced it would abandon the FDA filing for DME entirely. Oculis stock fell over 23% on the announcement.

Get Started